Clinical trial
Effect of Submucosal Cryotherapy With or Without Different Anti-inflammatory Drugs on Postoperative Pain and Interleukin-6 Levels in Maxillary Molars With Symptomatic Irreversible Pulpitis: A Randomized Clinical Study
NCT07919938 is registered in ClinicalTrials.gov with Suez Canal University as lead sponsor.
Follow this trial by email Email me the PDF
Summary
Not yet recruiting, started November 2026. Interventional study, Phase 3, 90 participants (estimated). Lead sponsor Suez Canal University; Egypt. Primary measure: Postoperative Pain Intensity Assessed Using the Numeric Rating Scale (NRS).
Registry record
As filed in ClinicalTrials.gov.
- Title
- Effect of Submucosal Cryotherapy With or Without Different Anti-inflammatory Drugs on Postoperative Pain and Interleukin-6 Levels in Maxillary Molars With Symptomatic Irreversible Pulpitis: A Randomized Clinical Study
- Lead sponsor
- Suez Canal University
- Phase
- Phase 3
- Overall status
- Not yet recruiting
- Start date
- November 15, 2026
- Completion date
- November 15, 2027
- Enrollment
- 90 (estimated)
- Sites
- 1
Conditions
MeSH condition names; the registry's own terms follow.
Who could take part, where it ran, who ran it
As filed in ClinicalTrials.gov.
- Sex
- All
- Minimum age
- 21 Years
- Maximum age
- 50 Years
- Healthy volunteers
- No
- Study type
- Interventional
- Sites
- 1
- Countries
- Egypt
- Lead sponsor
- Suez Canal University
Arms
As registered; 6 arms.
| Arm | Type | Interventions |
|---|---|---|
| Anesthesia Alone (Control Group) | Active comparator | Articaine Hydrochloride With Epinephrine |
Show registry wordingParticipants will receive local anesthesia using one carpule of 4% articaine hydrochloride with epinephrine 1:100,000 administered by buccal infiltration, with supplemental palatal infiltration if needed. Standardized single-visit root canal treatment will be performed without additional submucosal cryotherapy or anti-inflammatory drug injections. | ||
| Submucosal Cryotherapy With Anesthesia | Experimental | Articaine Hydrochloride With Epinephrine, Submucosal Cryotherapy |
Show registry wordingParticipants will receive standard local anesthesia followed by a single submucosal injection of 1 mL cold normal saline (2-5°C) into the buccal vestibule adjacent to the affected maxillary molar before standardized single-visit root canal treatment. | ||
| Diclofenac Sodium With Anesthesia | Experimental | Articaine Hydrochloride With Epinephrine, Diclofenac Sodium |
Show registry wordingParticipants will receive standard local anesthesia followed by a single submucosal injection of 1 mL diclofenac sodium (25 mg/mL; total dose 25 mg) into the buccal vestibule adjacent to the affected maxillary molar before standardized single-visit root canal treatment. | ||
| Dexamethasone With Anesthesia | Experimental | Articaine Hydrochloride With Epinephrine, Dexamethasone Sodium Phosphate |
Show registry wordingParticipants will receive standard local anesthesia followed by a single submucosal injection of 1 mL dexamethasone sodium phosphate (4 mg/mL; total dose 4 mg) into the buccal vestibule adjacent to the affected maxillary molar before standardized single-visit root canal treatment. | ||
| Submucosal Cryotherapy With Diclofenac Sodium | Experimental | Articaine Hydrochloride With Epinephrine, Diclofenac Sodium, Submucosal Cryotherapy |
Show registry wordingParticipants will receive standard local anesthesia followed by submucosal administration of cold normal saline (1 mL at 2-5°C) and diclofenac sodium (1 mL at 25 mg/mL) into the buccal vestibule adjacent to the affected maxillary molar before standardized single-visit root canal treatment. The interventions will be administered separately or sequentially according to the finalized study protocol. | ||
+1 more arm
Primary endpoints
Registered primary outcome measures; 1 primary.
| Measure | Time frame |
|---|---|
| Postoperative Pain Intensity Assessed Using the Numeric Rating Scale (NRS) | At 6, 12, 24, 48, and 72 hours after root canal treatment. |
Show registry wordingPostoperative pain intensity will be assessed using an 11-point Numeric Rating Scale (NRS), ranging from 0 (no pain) to 10 (worst imaginable pain). Higher scores indicate greater pain intensity. Participants will record their pain intensity at predefined postoperative intervals, and NRS scores will be compared among the six study groups. | |
Patents and exclusivity
By drug, as the FDA Orange Book declares its patents.
-
DEXAMETHASONE
- US 12144889; expires April 26, 2041; assignee Ocular Therapeutix, Inc
- US 11097061; expires June 23, 2039; assignee ICON Bioscience Inc
- US 10537585; expires December 18, 2037; assignee Dexcel Pharma Technologies Ltd.
- US 11304961; expires December 18, 2037; assignee Dexcel Pharma Technologies Ltd.
- US 11458041; expires November 16, 2037; assignee Ocular Therapeutix, Inc
- +7 more patents
-
Diclofenac
- US 11707443; expires December 8, 2040; assignee RK Pharma Inc.
- US 11850224; expires August 10, 2038; assignee RK Pharma Inc.
- US 11110073; expires March 23, 2038; assignee Zydus Lifesciences Limited (India)
- US 8546450; expires August 9, 2030; assignee Nuvo Research Inc.
- US 8679544; expires April 23, 2030; assignee iCeutica (United States)
- +37 more patents
Lead sponsor's other trials
Suez Canal University, most recent start first.
+158 more trials See the organization page
Similar trials
Same condition (Pulpitis) and phase, most recent start first.